Susceptibility Cards for Gram Negative Bacilli

VITEK® 2
MIC Calling GN66 GN67 GN68 GN69 GN70 GN71 GN72 GN73 GN74 GN75 GN76 GN77 GN79 GN80 GN81 GN82 GN83 GN84 GN86 GN87 GN90 GN91 GN92 GN93 *XN06
Class Antibiotic Range 413398 413399 413431 413400 413401 413402 413403 413404 413941 413432 413433 413434 413436 413437 413438 413439 413440 413410 413942 413943 414779 414780 414963 414985 413944
Amoxicillin / Clavulanic Acid 2/1 - 32/16
Aminopenicillin / inhibitor
Ampicillin 2 - 32
combination
Ampicillin / Sulbactam 2/1 - 32/16
Piperacillin 4 - 128
Piperacilllin / Tazobactam 4/4 - 128/4
Ureidopenicillin / inhibitor
combinations Ticarcillin 8 - 128
Ticarcillin / Clavulanic
8/2 - 128/2
Acid
Cefalotin 2 - 64
Cephalosporin I
Cefazolin 4 - 64
Cefotetan 4 - 64
Cephalosporin II /
Cefoxitin 4 - 64
Cephamycin
Cefuroxime 1 - 64
Cefepime 1 - 64
Cefotaxime 1 - 64
Cefpodoxime 0.25 - 8
Cephalosporin III / IV
Ceftazidime 1 - 64
Ceftizoxime 1 - 64
Ceftriaxone 1 - 64
Monobactam Aztreonam 1 - 64
ESBL ESBL Confirmation Test +/-
Doripenem 0.12 - 8
Ertapenem 0.5 - 8
Carbapenem
Imipenem 0.25 - 16
Meropenem 0.25 - 16
Amikacin 2 - 64
Aminoglycoside Gentamicin 1 - 16
Tobramycin 1 - 16
Ciprofloxacin 0.25 - 4
Levofloxacin 0.12 - 8
Fluroquinolone
Moxifloxacin 0.25 - 8
Norfloxacin 16 - 512
Tetracycline 1 - 16
Tetracyclines
Tigecycline 0.5 - 8
Nalidixic Acid 2 - 32
Nitrofurantoin 16 - 512
Miscellaneous
Trimethoprim / 20 (1/19) - 320
Sulfamethoxazole (16/304)
Go to www.totalast.com for more information and to get help in selecting your next VITEK 2® card. *mates to GN69 ©2018 BIOMÉRIEUX, INC. THE BLUE LOGO AND VITEK ARE REGISTERED TRADEMARKS OF BIOMÉRIEUX. PRINTED IN USA. 17 0285 02
Susceptibility Cards for Gram Positive Cocci AST-GP74 414971 S. pneumoniae Susceptibility Cards
(Staphylococcus spp., Enterococcus spp. and S. agalactiae)
Antibiotic MIC Calling Range FDA Indications for USE
MIC Calling GP67 GP72 GP75 GP78 Amoxicillin 0.06 - 8 S. pneumoniae
Antibiotic FDA Indications for USE
Range 22226 410770 415670 421051 Benzylpenicillin 0.06 - 8 SP(P&M)**
Ampicillin Cefotaxime 0.06 - 4 S. pneumoniae
Enterococcus spp. 2 - 32 Enterococcus spp. Ceftriaxone 0.06 - 4 S. pneumoniae
S. agalactiae 0.25 - 16 S. agalactiae Chloramphenicol 2 - 32 S. pneumoniae
Ertapenem 0.5 - 8 Spn except P(R)**
Ampicillin/Sulbactam 2/1 - 32/16 Staphylococcus spp.
Erythromycin (c) 0.25 - 1 S. pneumoniae
Benzylpenicillin
Levofloxacin 0.5 - 8 S. pneumoniae
Enterococcus spp. 0.12 - 64 Enterococcus spp.
Linezolid 2-4 S. pneumoniae
Staphylococcus spp. 0.03 - 0.5 Staphylococcus spp.
Meropenem 0.06 - 4 S. pneumoniae
S. agalactiae 0.12 - 64 S. agalactiae
Moxifloxacin 0.25 - 4 S. pneumoniae
Cefoxitin Screen NEG - POS Staphylococcus spp. Ofloxacin 1-8 S. pneumoniae
Ceftaroline 0.06-4 MRSA**, MSSA** Telithromycin 0.25 - 4 S. pneumoniae
Staphylococcus spp., Enterococcus spp., Tetracyclines 1 - 16 S. pneumoniae
Chloramphenicol 4 - 64
S. agalactiae
Trimethoprim / Sulfamethoxazole 10 (0.5/9.5) - 320 (16/304) S. pneumoniae
Ciprofloxacin 0.5 - 8 Staphylococcus spp., Enterococcus spp. Vancomycin 1-2 S. pneumoniae
Clindamycin 0.25 - 8 Staphylococcus spp., S. agalactiae Notes
Clindamycin 0.125 - 4 MSSA**, MSSE** c = Category agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five discrete dilutions.
**SP(P&M) = S. pneumoniae (pneumonia and meningitis), **Spn except P(R) = S. pneumoniae (excluding penicillin-resistant strains)
Daptomycin (NS) 0.12 - 8 S. aureus, VSEfaeca**
Doxycycline 0.5 - 16 S. aureus
Staphylococcus spp., Enterococcus spp., AST-ST02 420915 Streptococcus Susceptibility Cards
Erythromycin 0.25 - 8
S. agalactiae
Antimicrobial MIC Calling Range FDA Indications for USE
Gentamicin 0.5 - 16 Staphylococcus spp.
Ampicillin (NS2) 0.25 - 16 grpBetaHS**, grpVIR**
Gentamicin High Level (synergy) S-R Enterococcus spp. Benzylpenicillin (NS2) 0.06 - 8 grpC/G**, S. pyogenes, S. agalactiae, S. pneumoniae, grpVIR**
Inducible Clindamycin Resistance NEG - POS Staphylococcus spp. Cefotaxime 0.12 - 8 S. pneumoniae, SpyA**, Streptococcus spp.
Staphylococcus spp., Enterococcus spp., Ceftriaxone (NS2) 0.12 - 8 grpVIR**, S. agalactiae, S. pneumoniae, S. pyogenes
Levofloxacin 0.12 - 8
S. agalactiae Clindamycin (c) 0.25 - 1 SP(Pen(S))**, S. pyogenes, S. agalactiae, S. mitis, S. oralis
S. agalactiae, E. faecalis, E. faecium, S. Erythromycin 0.12 - 8 S. pneumoniae, S. pyogenes, grpVIR**
Linezolid 0.5 - 8
aureus, S. epidermidis, S. haemolyticus
Inducible Clindamycin Resistance
Minocycline 0.5 - 16 Staphylococcus spp., Enterococcus spp. NEG - POS S. agalactiae, S. pyogenes
S. agalactiae, S. pyogenes
Moxifloxacin 0.25 - 8 MSSA** SP+MDRSP**, S. pyogenes, grpC/F**, grpG**, S. agalactiae,
Levofloxacin 0.25 - 16
Nitrofurantoin 16 - 512 Staphylococcus spp., Enterococcus spp. grpVIR**, S. milleri
Oxacillin 0.25 - 4 Staphylococcus spp. Linezolid (NS2) 2-8 SP+MDRSP**, S. agalactiae, S. pyogenes
MSSA**, S. epidermidis, VREF**, S. S. anginosus, S. constellatus, SP+MDRSP**, S. pyogenes,
Quinupristin/Dalfopristin 0.25 - 16 Moxifloxacin 0.06 - 4
agalactiae S. agalactiae, grpVIR**
Rifampicin 0.5 - 32 Staphylococcus spp. Tetracyclines 0.25 - 16 S. pneumoniae, S. pyogenes, grpVIR**
Streptomycin High Level (synergy) S-R Enterococcus spp. SP(Pen(S))**, S. anginosus grp. (includes S. anginosus, S.
Tigecycline (NS) 0.06 - 1
intermedius, and S. constellatus), S. agalactiae, S. pyogenes
Staphylococcus spp., Enterococcus spp.,
Tetracycline 1 - 16 10 (0.5/9.5)
S. agalactiae Trimethoprim/Sulfamethoxazole (c) S. pneumoniae.
320 (16/304)
E. faecalis, E. faecium, S. aureus, S. epider-
Tigecycline (NS) 0.12 - 2 midis, S. haemolyticus, S. agalactiae, E. Vancomycin (NS) 0.12 - 8 grpVIR**, S. pyogenes, S. agalactiae
casseliflavus Notes
10 (0.5/9.5) NS2 = Beta-hemolytic Streptococci: The current absence of resistant isolates precludes defining any results other than susceptible. Isolates yielding MIC results sugges-
Trimethoprim/Sulfamethoxazole (c) S. aureus tive of Nonsusceptible category should be submitted to a reference laboratory for further testing. *grpBetaHS = Beta-hemolytic group Streptococcus species, *grpVIR
320 (16/304)
= Viridans group Streptococcus, *grpC/G = Beta-hemolytic Streptococcus groups C and G, *SpyA = S. pyogenes (Group A beta-hemolytic streptococci), c = Category
Enterococcus spp., Staphylococcus spp., S. agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five discrete dilutions. *SP(Pen(S)) = S.
Vancomycin 0.5 - 32
agalactiae pneumoniae (penicillin-susceptible strains) *SP+MDRSP = S. pneumoniae (including multi-drug resistant strains (MDRSP)) *grpC/F = Beta-hemolytic Streptococcus
groups C and F *grpG = Beta-hemolytic Streptococcus group G. NS = The current absence of resistant isolates precludes defining any results other than susceptible.
Notes Isolates yielding MIC results suggestive of Nonsusceptible category should be submitted to a reference laboratory for further testing.
NS = The current absence of resistant isolates precludes defining any results other than susceptible. Isolates yielding MIC results suggestive of Nonsusceptible category should
be submitted to a reference laboratory for further testing., *VSEfaeca = E. faecalis (vancomycin susceptible strains), *MSSA = Methicillin-susceptible S. aureus, *VREF = To order please visit: www.biomerieuxDIRECT.com
Vancomycin-resistant E. faecium, c = Category agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five
discrete dilutions. *MRSA = Methicillin-resistant S. aureus, *MSSE = Methicillin-susceptible S. aureus,